1. Search Result
Search Result
Results for "

Hybrid compound

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N7093

    Strawberry furanone

    Environmental Pollutants Quinone Reductase Fungal Bacterial Infection
    Furaneol is mainly isolated from American grape (Vitis labrusca) and its hybrid grape. Furaneol is an important aroma compound in fruits and contribute to the strawberry-like note in some wines .
    Furaneol
  • HY-107987

    CXCR Endocrinology
    CXCR7 modulator 1 (compound 25) is a potent and orally bioavailable peptoid hybrid CXCR7 modulator, with a Ki of 9 nM .
    CXCR7 modulator 1
  • HY-N7093R

    Strawberry furanone (Standard)

    Reference Standards Bacterial Fungal Quinone Reductase Infection
    Furaneol (Standard) is the analytical standard of Furaneol. This product is intended for research and analytical applications. Furaneol is mainly isolated from American grape (Vitis labrusca) and its hybrid grape. Furaneol is an important aroma compound in fruits and contribute to the strawberry-like note in some wines .
    Furaneol (Standard)
  • HY-149958

    Parasite Infection
    Antileishmanial agent-17 is a coumarin hybrid compound with antileishmanial effects (IC50 <0.78 μM). Antileishmanial agent-17 is safe to normal VERO cells. Antileishmanial agent-17 binds to folate pathway enzymes pteridine reductase and DHFR-TS. And Antileishmanial agent-17 shows the most potent with IC50 value of 0.40 μM against promastigote and 0.68 μM against amastigote, respectivley.
    Antileishmanial agent-17
  • HY-145294

    ROCK Neurological Disease
    ROCK2-IN-5 (compound 1d) is a hybrid compound containing structural fragments of the Rho kinase inhibitor fasudil and the NRF2 inducers caffeic and ferulic acids. ROCK2-IN-5 has good multitarget profile and good tolerability. ROCK2-IN-5 has the potential for thr research of Amyotrophic lateral sclerosis (ALS) with a SOD1 mutation .
    ROCK2-IN-5
  • HY-118295

    Endogenous Metabolite Cancer
    Pyrimidine-indole hybrid is a compound that inhibits ciliogenesis and has the activity of antagonizing the Hedgehog signaling pathway by destabilizing microtubules. Pyrimidine-indole hybrid exerts its biological effects by inhibiting ciliogenesis and deconstructing the stable form of α-tubulin. Pyrimidine-indole hybrid has shown its unique mechanism of action in in vitro cell experiments and zebrafish embryo models, interfering with microtubule dynamics .
    Pyrimidine-indole hybrid
  • HY-119673

    Antibiotic Others
    Lincophenicol is a hybrid antibiotic that has the activity of inhibiting the puromycin reaction catalyzed by Escherichia coli ribosomal peptidyl transferase and also inhibits the binding of specific compounds to the Escherichia coli ribosome.
    Lincophenicol
  • HY-161340

    Apoptosis Cancer
    Anti-melanoma agent 2 (Compound IId) is a steroid hybrid that effectively induces endoplasmic reticulum stress (ERS) and causes apoptosis. Anti-melanoma agent 2 shows anti-melanoma effects .
    Anti-melanoma agent 2
  • HY-N11880

    COX Cancer
    2-O-Sinapoyl makisterone A (compound 2), a sinapinic acid-ecdysterone hybrid, is a selective inhibitor of COX-2. 2-O-Sinapoyl makisterone A significantly inhibits the expression of COX-2 protein .
    2-O-Sinapoyl makisterone A
  • HY-128346

    Amyloid-β Neurological Disease
    PQM130, a Feruloyl-Donepezil Hybrid compound with brain penatration, is a multitarget agent candidate against the neurotoxicity induced by Aβ1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 acts as a neuroprotective compound for anti-AD agent development .
    PQM130
  • HY-156188

    Cholinesterase (ChE) Others
    AChE-IN-41 (Compound 2) is a compound of the Galantamine Memantine hybrid. AChE-IN-41 has the inhibition ability of cholinesterase. AChE-IN-41 shows higher plasma stability and comparable microsomal stability in vitro, while showing lower half-life and faster clearance in vivo .
    AChE-IN-41
  • HY-173213

    Parasite Infection Inflammation/Immunology
    Antileishmanial agent-33 (4e), a hybrid compound of grandisin and machilin G, shows moderate activity on promastigotes (IC50 of 38.1 μM). Antileishmanial agent-33 (4e) shows potential as an antileishmanial agent for the research of cutaneous leishmaniasis (CL) .
    Antileishmanial agent-33
  • HY-146174

    Potassium Channel Cardiovascular Disease
    KCa1.1 channel activator-2 (compound 3F), a Quercetin hybrid derivative, is a selective vascular KCa1.1 channel stimulator. KCa1.1 channel activator-2 exhibits potent myorelaxant activity .
    KCa1.1 channel activator-2
  • HY-162170

    NF-κB Keap1-Nrf2 p38 MAPK Inflammation/Immunology
    Anti-inflammatory agent 72 (compound 5) is a novel resveratrol derivative hybrid with benzoylhydrazine. Anti-inflammatory agent 72 shows anti-inflammatory and antioxidant activities by activating Nrf2 and inhibiting NF-κB p65/iNOS and MAPKs signaling pathways .
    Anti-inflammatory agent 72
  • HY-115970

    Microtubule/Tubulin Cancer
    Tubulin inhibitor 21 (compound 6f), a chalcone- and melatonin- based hybrid, is a potent tubulin inhibitor. Tubulin inhibitor 21 induces a remarkable cytotoxic activity toward SW480 cells (IC50=0.26 μM) with lower effect against nonmalignant cells .
    Tubulin inhibitor 21
  • HY-W598230A

    Biochemical Assay Reagents Others
    m-PEG2000-NH2 hydrochloride is a barrier permeation compound involved in the preparation of hybrid gels with adsorption and size exclusion chromatography (AdSEC) properties. m-PEG-NH2 helps AdSEC gels separate from complex biological mixtures such as blood, urine, sweat, and tears.
    m-PEG2000-NH2 hydrochloride
  • HY-163899

    Phosphatase Metabolic Disease
    (+)-Crinatusin A1 (Compound (+)- 4) is a chalcone-monoterpene hybrid, which can be isolated from Cleistocalyx operculatus. (+)-Crinatusin A1 is an inhibitor for protein tyrosine phosphatase 1B (PTP1B) with IC50 of 0.9 μM. (+)-Crinatusin A1 exhibits potential as an antidiabetic agent .
    (+)-Crinatusin A1
  • HY-145908

    NO Synthase Cancer
    Antitumor agent-49 (Compound 10) is a Harmine derivative-furoxan hybrids containing NO donor, with antitumor activities. Antitumor agent-49 shows cytotoxic activity against HepG2 cells with an IC50 of 1.79 µM. Antitumor agent-49 produces high levels of NO in vitro .
    Antitumor agent-49
  • HY-124499

    Integrin Cardiovascular Disease
    RUC-1 (Compound 1) is an inhibitor for αIIbβ3 integrin. RUC-1 inhibits fibrin deposition and platelet aggregation in hybrid hαIIb/mβ3 receptors expressing mice. RUC-1 exhibits antithrombotic effect in hαIIb/mβ3 receptor expressing mice .
    RUC-1
  • HY-146173

    Potassium Channel Calcium Channel Cardiovascular Disease
    KCa1.1 channel activator-1 (compound 1E), a Quercetin hybrid derivative, is a selective vascular KCa1.1 channel channel stimulator. KCa1.1 channel activator-1 also displays CaV1.2 channel blocking activity. KCa1.1 channel activator-1 exhibits weak myorelaxant activity .
    KCa1.1 channel activator-1
  • HY-162390

    Amylases Glycosidase Endocrinology
    α-Amylase/α-Glucosidase-IN-11 (Compound 5d) is a isoxazolidine-isatin hybrid with significant antidiabetic activity. α-Amylase/α-Glucosidase-IN-11 competitively inhibits α-amylase (IC50 = 30.39 μM) and α-glucosidase (IC50 = 65.1 μM), two key digestive enzymes. α-Amylase/α-Glucosidase-IN-11 does not cross the blood-brain barrier .
    α-Amylase/α-Glucosidase-IN-11
  • HY-14988

    Bacterial Infection
    I-A09 and its derivatives, specifically 1,2,3-triazole-adamantylacetamide hybrids (5a–u), exhibit significant antitubercular activity. These hybrids were synthesized using copper-catalyzed click chemistry, combining bioactive fragments from antitubercular I-A09 and substituted adamantyl urea. The compound N-(1-adamantyl)-2-azido acetamide was reacted with various alkyl/aryl acetylenes to produce new analogues. Among them, N-(1-adamantan-1-yl)-2-(4-(phenanthren-2-yl)-1H-1,2,3-triazol-1-yl)acetamide (5t) showed the most promise with a minimum inhibitory concentration (MIC) of 3.12 μg/mL against Mycobacterium tuberculosis H37Rv, and a selectivity index greater than 15 .
    I-A09
  • HY-162828

    STAT HDAC Cancer
    STAT3/HDAC-IN-2 (compound 18) is a dual inhibitor of STAT3 and HDAC, inducing autophagy and apoptosis. STAT3/HDAC-IN-2 is an amphiphilic hydroxamic acid hybrid based on the natural product isopropanol lactone (IAL) and is a nanoscale anticancer agent. STAT3/HDAC-IN-2 can self-assemble in water to form nanoparticles, which have higher tumor tissue accumulation, cellular uptake and anticancer properties compared to the free state .
    STAT3/HDAC-IN-2
  • HY-162856

    TRP Channel Neurological Disease
    TRPV1-IN-2 ((R)-32) is a TRPV1 inhibitor. TRPV1-IN-2 has protective effects on ED epilepsy models .
    TRPV1-IN-2
  • HY-162805

    NO Synthase Topoisomerase Apoptosis NF-κB Inflammation/Immunology Cancer
    iNOS/TopoI-IN-1 (compound AuL9) is a multi-target hybrid molecule with anti-tumor, anti-inflammatory and antioxidant activities. iNOS/TopoI-IN-1 inhibits the growth of breast cancer cells MCF-7 and MDA MB-231 in vitro with IC50 of 3.5 μM and 6.3 μM, respectively, and induces DNA damage and apoptosis of breast cancer cells by inhibiting human topoisomerase I (TopoI) (Ki=2.72 μM). In addition, NOS/TopoI-IN-1 inhibits the expression of iNOS by inhibiting the activation of NF-kB (Ki=1.49 μM) .
    iNOS/TopoI-IN-1
  • HY-121465

    Endogenous Metabolite Metabolic Disease
    Stearoyl serotonin is a hybrid molecule patterned after arachidonoyl serotonin. Arachidonoyl serotonin is a dual antagonist of fatty acid amide hydrolase (FAAH) and the transient receptor potential vanilloid-type 1 (TRPV1) channel, reducing both acute and chronic peripheral pain. The effects of replacing the arachidonoyl portion with the saturated 18-carbon stearoyl moiety have not been studied. However, replacement of arachidonate with saturated 11- or 12-carbon fatty acids produces compounds that potently inhibit capsaicin-induced TRPV1 channel activation (IC50=0.76 μM) without blocking FAAH-mediated hydrolysis of arachidonoyl ethanolamine (IC50 > 50 μM).
    Stearoyl Serotonin
  • HY-177958

    Lactate Dehydrogenase Glutathione S-transferase Cholinesterase (ChE) Parasite Infection Cancer
    ACS03 is a hybrid thiophene-acridine compound. ACS03 induces an increase in lactate dehydrogenase, glutathione S-transferase, and AChE activities. ACS03 has antileishmanial activity. ACS03 exhibits selective anti-cancer effects against colon carcinoma .
    ACS03
  • HY-107987R

    Reference Standards CXCR Endocrinology
    CXCR7 modulator 1 (Standard) is the analytical standard of CXCR7 modulator 1 (HY-107987). This product is intended for research and analytical applications. CXCR7 modulator 1 (compound 25) is a potent and orally bioavailable peptoid hybrid CXCR7 modulator, with a Ki of 9 nM .
    CXCR7 modulator 1 (Standard)
  • HY-179526

    Apoptosis PARP Cancer
    Sino-C is a Sinomenine (HY-15122) derivative with anticancer activity. Sino-C broadly disrupts cholesterol homeostasis by upregulating key genes such as SREBF2 and HMGCS1, leading to intracellular cholesterol accumulation and lipid droplet formation. Sino-C-induced metabolic dysregulation further triggers lipid peroxidation and endoplasmic reticulum (ER) stress, initiating a unique form of hybrid cell death including apoptotic (cleaved PARP) and necrotic-like features. Sino-C thus serves as a useful compound for research in colorectal cancer, lung cancer and breast cancer .
    Sino-C
  • HY-176947

    Drug Intermediate Cancer
    Demethyl-sapanisertib-C2-amide-PEG7-C2-N3 (Compound 10c) is an azide group linker used for coupling, which can be employed in the synthesis of "Rapa-Link" compounds, such as M-1111 (HY-176948), an mTOR inhibitor .
    Demethyl-sapanisertib-C2-amide-PEG7-C2-N3
  • HY-176948

    mTOR Cancer
    M-1111 is a Rapa-Link inhibitor. M-1111 is covalently linked by Rapamycin (HY-10219) and an inhibitor of the active site mTOR. M-1111 has strong inhibitory activity on the mTORC1 signaling pathway (pS6 and p4E-BP1). M-1111 has nanomolar-level inhibitory activity against various cancer cells. M-1111 completely inhibits p4E-BP1 without inhibiting pAkt S473. M-1111 can be used for research on liver cancer, kidney cancer, and colorectal cancer .
    M-1111

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: